FDA relaxes cardiovascular trial requirements for diabetes drugs

被引：0

|

作者：

Asher Mullard ^{[
]}

机构：

来源：

Nature Reviews Drug Discovery | 2020年 / 19卷 / 5期

关键词：

D O I：

10.1038/d41573-020-00071-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：298 / 298

相关论文

共 50 条

[1] FDA relaxes cardiovascular trial requirements for diabetes drugs
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (05) : 298 - 298
[2] Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs? Ten Years of FDA Guidance Requirements to Evaluate Cardiovascular Risk
Wang, Cecilia C. Low
Everett, Brendan M.
Burman, Kenneth D.
Wilson, Peter W. F.
CIRCULATION, 2019, 139 (14) : 1741 - 1743
[3] FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on
Asher Mullard
Nature Reviews Drug Discovery, 2018, 17 : 850 - 851
[4] FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (12) : 850 - 851
[5] FDA cGMP Requirements for PET Drugs
Norenberg, Jeffrey P.
Schwarz, Sally
VanBrocklin, Henry
JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (05) : 16N - 16N
[6] The New FDA Pregnancy Labeling Requirements for Drugs
Frederiksen, Marilynn C.
JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2011, 56 (03) : 303 - 307
[7] Postmarketing requirements for new drugs approved by the FDA
Reactions Weekly, 2022, 1895 (1) : 8 - 8
[8] FDA approach to the regulation of drugs for diabetes
Fleming, A
AMERICAN HEART JOURNAL, 1999, 138 (05) : S338 - S345
[9] Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice
Bethel, M. Angelyn
Sourij, Harald
CURRENT CARDIOLOGY REPORTS, 2012, 14 (01) : 59 - 69
[10] Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice
M. Angelyn Bethel
Harald Sourij
Current Cardiology Reports, 2012, 14 : 59 - 69

← 1 2 3 4 5 →